etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics
News provided by
Share this article
Share this article
GAINESVILLE, Fla., Jan. 14, 2021 /PRNewswire/ Digital health company, etectRx, Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to explore the use of digital pill solutions with PDTs. This collaboration between etectRx and Pear Therapeutics comes at a critical time for the mental health field, an area that is in dire need of immediate solutions, said Valerie Sullivan, president and CEO of etectRx. Our goal for this collaboration is to bring concrete solutions to those who need it.